GCL Energy Technology (002015.SZ) subsidiary plans to invest 100 million yuan to participate in the Lishi Xing Shen Fund.
Xiexin Energy Technology Co., Ltd. (002015.SZ) announced that its wholly-owned subsidiary, Xinneng Wei Lai (Suzhou) Industrial Investment Co., Ltd., as one of the limited partners (LP), has recently signed a partnership agreement with the general partner (GP) Tianjin Li Si Ming Tang Enterprise Management Consulting Partnership (Limited Partnership) and other limited partners. The company plans to invest 100 million yuan of its own funds to participate in the subscription of partnership shares in Tianjin Li Si Xing Shen Equity Investment Partnership (Limited Partnership) (referred to as "Li Si Xing Shen"). The initial fundraising scale of this fund is 1.74 billion yuan, which will mainly target emerging technology-related fields.
GCL Energy Technology (002015.SZ) announced that recently, its wholly-owned subsidiary, Xin Weilai (Suzhou) Industrial Investment Co., Ltd., as one of the limited partners (LP), signed a partnership agreement with general partner (GP) Tianjin Lisi Mingtang Enterprise Management Consulting Partnership (Limited Partnership) and other limited partners. The company intends to use its own funds to contribute 100 million yuan to participate in the subscription of partnership interests in Tianjin Lisi Xing Shen Equity Investment Partnership (Limited Partnership) (referred to as "Lisi Xing Shen"). The initial fundraising scale of this fund is 1.74 billion yuan and will primarily focus on emerging technology-related fields.
Related Articles
Threes (605168.SH) plans to launch a restricted stock incentive plan in 2026.
HUAJIN INTL (02738) stated that it is unaware of the reason for the stock price fluctuation.
Wu Yusheng, the chairman, executive director, and president of TYK MEDICINES-B (02410), intends to increase his shareholding in the company.
Threes (605168.SH) plans to launch a restricted stock incentive plan in 2026.
HUAJIN INTL (02738) stated that it is unaware of the reason for the stock price fluctuation.
Wu Yusheng, the chairman, executive director, and president of TYK MEDICINES-B (02410), intends to increase his shareholding in the company.
RECOMMEND
